EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer

Vicenç Ruiz de Porras, Adrià Bernat-Peguera, Clara Alcon, Fernando Laguia, Maria Fernández-Saorin, Natalia Jiménez, Ana Senan-Salinas, Carme Solé-Blanch, Andrea Feu, Mercedes Marín-Aguilera, Juan Carlos Pardo, Maria Ochoa-de-Olza und 3 weitere

Frontiers in Pharmacology · 22.01.2024 · 15

DOI: 10.3389/fphar.2024.1331648 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 22.01.2024. Verfasst von Vicenç Ruiz de Porras und 14 weiteren Autor:innen. Beteiligte Einrichtung: CARE Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Docetaxel remains the standard treatment for metastatic castration-resistant prostate cancer (mCRPC). However, resistance frequently emerges as a result of hyperactivation of the PI3K/AKT and the MEK/ERK pathways. Therefore, the inhibition of these pathways presents a potential therapeutic approach. In this study, we evaluated the efficacy of simultaneous inhibition of the PI3K/AKT and MEK/ERK pathways in docetaxel-resistant mCRPC, both in vitro and in vivo .

Methods

Docetaxel-sensitive and docetaxel-resistant mCRPC cells were treated with selumetinib (MEK1/2 inhibitor), AZD8186 (PI3Kβ/δ inhibitor) and capivasertib (pan-AKT inhibitor) alone and in combination. Efficacy and toxicity of selumetinib+AZD8186 were tested in docetaxel-resistant xenograft mice. CRISPR-Cas9 generated a PTEN-knockdown docetaxel-resistant cell model. Changes in phosphorylation of AKT, ERK and downstream targets were analyzed by Western blot. Antiapoptotic adaptations after treatments were detected by dynamic BH3 profiling.

Results

PI3K/AKT and MEK/ERK pathways were hyperactivated in PTEN-wild-type (wt) docetaxel-resistant cells. Selumetinib+AZD8186 decreased cell proliferation and increased apoptosis in PTEN-wt docetaxel-resistant cells. This observation was further confirmed in vivo , where docetaxel-resistant xenograft mice treated with selumetinib+AZD8186 exhibited reduced tumor growth without additional toxicity.

Conclusion

Our findings on the activity of selumetinib+AZD8186 in PTEN-wt cells and in docetaxel-resistant xenograft mice provide an excellent rationale for a novel therapeutic strategy for PTEN-wt mCRPC patients resistant to docetaxel, in whom, unlike PTEN-loss patients, a clinical benefit of treatment with single-agent PI3K and AKT inhibitors has not been demonstrated. A phase I-II trial of this promising combination is warranted.

Schlagwörter

Stichwörter der Autor:innen

AZD8186PTEN statusmetastatic castration-resistant prostate cancerselumetinibtaxane resistance

Autor:innen und Institutionen

  • CARE Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
  • Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Barcelona, Spain.
  • GRET and Toxicology Unit, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.
  • Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.
  • IrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
  • Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain.

Zitieren

APA

Ruiz de Porras, V., Bernat-Peguera, A., Alcon, C., Laguia, F., Fernández-Saorin, M., Jiménez, N., Senan-Salinas, A., Solé-Blanch, C., Feu, A., Marín-Aguilera, M., Pardo, J. C., Ochoa-de-Olza, M., Montero, J., Mellado, B., & Font, A. (2024). Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1331648

Vancouver

Ruiz de Porras V, Bernat-Peguera A, Alcon C, Laguia F, Fernández-Saorin M, Jiménez N, et al. Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1331648

BibTeX
@article{RuizdePorras2024,
  author = {Ruiz de Porras, Vicenç and Bernat-Peguera, Adrià and Alcon, Clara and Laguia, Fernando and Fernández-Saorin, Maria and Jiménez, Natalia and Senan-Salinas, Ana and Solé-Blanch, Carme and Feu, Andrea and Marín-Aguilera, Mercedes and Pardo, Juan Carlos and Ochoa-de-Olza, Maria and Montero, Joan and Mellado, Begoña and Font, Albert},
  title = {Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1331648}
}
Kostenlos starten →